



Chlorion Pharma Announces Dr. Franz Hefti as its New Chief Development Officer

LAVAL, QC, November 17 -- Chlorion Pharma Inc. today announced that Dr. Franz Hefti will assume the role of Vice President & Chief Development Officer for the corporation.

In this capacity, Dr. Hefti will oversee all aspects of clinical and non-clinical drug development.

“Dr. Hefti is one of the world’s top drug researchers”, said Dr. Jeffrey Coull, Chlorion’s President & Acting CEO. “Our company is truly privileged to be able to work with – and be guided by – an expert of this caliber”.

In his over twenty years of experience in the pharmaceutical research & development space, Dr. Hefti has held leadership roles in both full-scale pharmaceutical companies and smaller biotechnology companies. Most recently, he oversaw development at Avid Radiopharmaceuticals and Rinat Neuroscience. Prior to this, Dr. Hefti headed worldwide neuroscience research at Genentech and later at Merck.

During his career in industry and academia, he has published over 250 papers on neurotrophic factors and topics in neuropharmacology, as well as a recent textbook entitled "Drug Discovery for Nervous System Diseases" (John Wiley & Sons).

About the Company

Chlorion Pharma Inc. is a biopharmaceutical company focused on neurotherapeutics that act via the modulation of chloride in the central nervous system. Presently, the company is developing first-in-class therapeutics for the treatment of neuropathic pain and epilepsy.

For more information, please visit our website at www.chlorion.com.

##